PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Markus Follmann	10/23/2010
Volkmar Wehner	10/26/2010
Jerome Meneyrol	11/10/2010
Jean-Michel Altenburger	11/09/2010
Frederic Petit	11/09/2010
Gilbert Lassalle	11/10/2010
Jean-Pascal Herault	11/10/2010

RECEIVING PARTY DATA

Name:	sanofi-aventis
Street Address:	174 Avenue de France
City:	Paris
State/Country:	FRANCE
Postal Code:	75013

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	12858991

CORRESPONDENCE DATA

Fax Number: (908)231-2626

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 908-231-2551

Email: linda.remer@sanofi-aventis.com

Correspondent Name: Ronald G. Ort
Address Line 1: 1041 Route 202-206
Address Line 2: Mail Code: D303-A

Address Line 4: Bridgewater, NEW JERSEY 08807

ATTORNEY DOCKET NUMBER: DE2008/020 US CNT

501410943 REEL: 025664 FRAME: 0906

12858991

PATENT

NAME OF SUBMITTER:	Linda J. Remer
Total Attachments: 4 source=DE2008-020 USCNT EXECUTED A source=DE2008-020 USCNT EXECUTED A source=DE2008-020 USCNT EXECUTED A source=DE2008-020 USCNT EXECUTED A	ASSIGN#page2.tif ASSIGN#page3.tif

DE 2008/020 US CNT

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Markus Follmann, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 2) Dr. Volkmar Wehner, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Jerome Meneyrol, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 4) Jean-Michel Altenburger, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 5) Frédéric Petit, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 6) Gilbert Lassalle, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 7) Jean-Pascal Herault, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France

The Inventors are citizens of: 1) - 2) Germany; 3) - 7) France

hereby sell, assign, and transfer unto **sanofl-aventis**, a corporation organized under the laws of **France**, located at **174 avenue de France**, **75013 Paris**, **France**,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 12/858,991

filed: August 18, 2010

entitled: Chlorothiophene-amides as inhibitors of coagulation factors Xa and thrombin

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inve	ntor(s):	
1 st :	Marker &	Date: 10/23/2010
	(Markus Follmann)	
2 nd :		Date:
	(Volkmar Wehner)	
3 rd :		Date:
.	(Jerome Meneyrol)	
4 th :		Dete:
-	(Jean-Michel Altenburger)	Date:
5 th :		Data
o :	(Frédéric Petit)	Date:
_th		
6 th :	(Gilbert Lassalle)	Date:
	(Gilbert Edeballe)	
7 th :	Section Control of the Control of th	Date:
	(Jean-Pascal Herault)	

DE 2008/020 US CNT

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Markus Follmann, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 2) Dr. Volkmar Wehner, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Jerome Meneyrol, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 4) Jean-Michel Altenburger, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 5) Frédéric Petit, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Parls, France
- 6) Gilbert Lassalle, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 7) Jean-Pascal Herault, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France

The inventors are citizens of: 1) - 2) Germany; 3) - 7) France

hereby sell, assign, and transfer unto **sanofi-aventis**, a corporation organized under the laws of **France**, located at **174 avenue de France**, **75013 Paris**, **France**,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 12/858,991

filed: August 18, 2010

entitled: Chlorothiophene-amides as inhibitors of coagulation factors Xa and thrombin

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):

1 st:		Date:
	(Markus Follmann)	. 1
2 nd :	Colema Clolen	Date: 26.10.2010
	(Volkmar Wehner)	•
3 rd :		Date:
	(Jerome Meneyrol)	
4 th :		Date:
	(Jean-Michel Altenburger)	
5 th :		Date:
	(Frédéric Petit)	
6 th :		Date:
	(Gilbert Lassalle)	
7 th :		Date:
	(Jean-Pascal Herault)	

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Markus Follmann, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 2) Dr. Volkmar Wehner, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Jerome Meneyrol, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 4) Jean-Michel Altenburger, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 5) Frédéric Petit, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 6) Gilbert Lassalle, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 7) Jean-Pascal Herault, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France

The inventors are citizens of: 1) - 2) Germany; 3) - 7) France

hereby sell, assign, and transfer unto **sanofi-aventis**, a corporation organized under the laws of **France**, located at **174 avenue de France**, **75013 Paris**, **France**,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 12/858,991

filed: August 18, 2010

entitled: Chlorothiophene-amides as inhibitors of coagulation factors Xa and thrombin

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):

1 st :		Date:
•	(Markus Follmann)	
2 nd :		Date:
	(Volkmar Wehner)	
3 rd :		Date:
	(Jerome Meneyup)	Date: 9. 11. 2010
4 th :		Date:
5 th :	(Jean-Michel Afrenburger)	Date: 9 /11/2010
Ο.	(Frédéric Petit)	
6 th :		Date:
	(Gilbert Lassalle)	
7 th :		Date:
	(Jean-Pascal Herault)	

DE 2008/020 US CNT

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

- 1) Dr. Markus Follmann, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 2) Dr. Volkmar Wehner, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Jerome Meneyrol, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 4) Jean-Michel Altenburger, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 5) Frédéric Petit, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 6) Gilbert Lassalle, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France
- 7) Jean-Pascal Herault, c/o sanofi-aventis, Département Brevet, 174, Avenue de France, 75015 Paris, France

The Inventors are citizens of: 1) - 2) Germany; 3) - 7) France

hereby sell, assign, and transfer unto sanofi-aventis, a corporation organized under the laws of France, located at 174 avenue de France, 75013 Paris, France,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 12/858,991

filed:

August 18, 2010

entitled:

Chlorothiophene-amides as inhibitors of coagulation factors Xa and thrombin

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

inventor(s):

1 st :		Date:
• •	(Markus Follmann)	
2 nd :		Date:
	(Volkmar Wehner)	10/11/10/16
3 rd :		Date: 10/11/2010
•	(Jerome Meneyrol)	•
4 th :		Date:
٠.	(Jean-Michel Altenburger)	
5 th :		Date:
J .	(Frédéric Petit)	
6 th :	10Hors	Date: 10/11/2010
•	(Gilbert Lassalle)	, ,
7 th .	Warner !	Date: 10/11/2010
r .	(Joan Passel Harault)	

PATENT REEL: 025664 FRAME: 0911

RECORDED: 01/20/2011